title: Imatinib mesylate treatment for a Chinese patient with metastatic and recurrent dermatofibrosarcoma protuberans:  is sustained partial remission possible?
authors.forename: Chunmeng
authors.initials: C
authors.lastname: Wang
authors.forename: Zhiguo
authors.initials: Z
authors.lastname: Luo
authors.forename: Biqing
authors.initials: B
authors.lastname: Zheng
authors.forename: Yong
authors.initials: Y
authors.lastname: Chen
authors.forename: Xi
authors.initials: X
authors.lastname: Cao
authors.forename: Jian
authors.initials: J
authors.lastname: Wang
authors.forename: Ruming
authors.initials: R
authors.lastname: Zhang
authors.forename: Yingqiang
authors.initials: Y
authors.lastname: Shi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D018223:Dermatofibrosarcoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate